Jazz Pharma, AbCellera ink antibody deal worth up to $876 million

Jazz Pharmaceuticals signed a research collaboration and licensing agreement with AbCellera to develop T-cell engaging multispecific antibodies for cancer. The deal adds a new oncology R&D partnership and expands Jazz's pipeline optionality, though no financial terms or clinical data were disclosed. The announcement is constructive for both companies but is unlikely to move the broader market materially.

Analysis

Jazz Pharmaceuticals signed a research collaboration and licensing agreement with AbCellera to develop T-cell engaging multispecific antibodies for cancer. The deal adds a new oncology R&D partnership and expands Jazz's pipeline optionality, though no financial terms or clinical data were disclosed. The announcement is constructive for both companies but is unlikely to move the broader market materially.